| |
|
May
2, 2005 |
|
|
|
|
|
REIMBURSEMENT
• CMS Considers Refining
Coronary Artery Stent DRGs |
|
MEDICAL
LIABILITY REFORM
• McClellan
Testifies on Medical Liability Reform
• Arizona Liability
Legislation Becomes Law
|
|
QUALITY
IMPROVEMENT
• Senate Considers
Additional CDC Funding
• “Patient
Navigator” Bill Advances in
Both Houses
• Drug Safety Bill
Introduced
• Defibrillator
Cables Recalled
|
REIMBURSEMENT |
|
CMS
Considers Refining Coronary Artery
Stent DRGs
As
part of a proposed rule released by
the Centers for Medicare and Medicaid
Services (CMS) last week, diagnostic
related groups (DRGs) associated with
insertion of coronary artery stents
would be refined to improve the accuracy
of payment. The
proposal would replace DRGs 516
and 526 with four new DRGs to reflect
the presence or absence of a secondary
diagnosis on a list of comorbidities
and complications. DRGs with secondary
diagnoses would be assigned higher
weights and reimbursed at a higher
amount than those without. The
ACC will review the proposed rule,
which will be published May 5 in the
Federal Register, and will
provide comments as appropriate. |
| MEDICAL
LIABILITY REFORM |
|
McClellan
Testifies on Medical Liability Reform
On
April 28, CMS Administrator Mark McClellan,
M.D., Ph.D., testified on medical
liability reform before the Joint
Economic Committee, one of the only
legislative committees composed of
lawmakers from both the Senate and
the House of Representatives. McClellan
emphasized that the current system
is not only expensive but unfair to
patients with just cause for seeking
compensation for their injuries. The
burdensome process for patients and
physicians needs to be expeditiously
addressed by Congress, McClellan said,
by implementing reforms
such as caps on noneconomic damages,
revisions to collateral source rules
and abolition of punitive damages.
Click
here to read Dr. McClellan’s
written testimony.
|
Arizona
Liability Legislation Becomes Law
Arizona
Gov. Janet Napolitano signed legislation
last week designed to facilitate open
communication between physicians and
patients without fear of legal repercussions.
The law allows providers to express
sympathy or apology and prevents these
statements from being used in court.
The law also stipulates that medical
experts testifying
in medical liability cases must be licensed
physicians actively practicing in the
relevant specialty.
|
| QUALITY
IMPROVEMENT |
|
Senate
Considers Additional CDC Funding
Last
week, the Senate Health, Education,
Labor and Pensions (HELP) Committee
approved a bill that would provide
an additional $1 million in funding
to the National Foundation for the
Centers for Disease Control and Prevention.
The Foundation is currently funded
at $500,000. The bill, sponsored by
Sens. Johnny Isakson, R-Ga., and Saxby
Chambliss, R-Ga., now goes to the
full Senate for its consideration.
|
|
“Patient
Navigator” Bills Advance in
Both Houses
The
Senate HELP Committee and the House
Energy and Commerce Health Subcommittee
approved bills that would allocate
$25 million in grants over the next
five years to programs that help patients
obtain health care services. Award
recipients will use the money to hire
“patient navigators,”
who will help patients coordinate
chronic disease screenings and other
preventive care services, identify
clinical trials, understand insurance
policies and apply for federal assistance
from government programs such as Medicaid
and Medicare. The bills are
designed to help low-income, rural
and uninsured patients obtain medical
care.
|
Drug
Safety Bill Introduced
Sens.
Chuck Grassley, R-Iowa, and Christopher
Dodd, D-Conn., introduced a sweeping
reform bill last week aimed at more
strictly regulating post-market surveillance
of prescription drugs. The bill would
establish the Center for Post-market
Drug Evaluation and Research (CPDER),
an independent office within the Food
and Drug Administration (FDA), that
would have the authority to require
manufacturers to conduct post-market
trials of new drugs, add label warnings
or restrict distribution for medications
and fine pharmaceutical companies that
do not comply with CPDER decisions.
“This measure will save patients’
lives, help restore consumer confidence
in the safety of prescription drugs
and ensure that the words ‘FDA
Approved’ continue to be the gold
standard for safety and quality,”
Dodd said. Click
here to read the press release. |
Defibrillator
Cables Recalled
The
FDA and the Laerdal Medical Corporation
notified healthcare professionals of
a voluntary recall of more than 3,000
defibrillator adapter cables due to
reports of broken wires within the cables
that prevented shocks from being administered
to patients. The recall affects all
lots of CM 100-Heartstart Adapter Cable,
Cat. No. 920650. Click
here to read the company's recall
announcement. |
| Questions?
Comments? Send your feedback to epubs@acc.org
and include the name of the publication
in the subject line. |
|
|
|
|
|
|
Back to Top |
| Copyright © 2008 American College of Cardiology
Heart House | 2400 N Street, NW | Washington, DC 20037
|
|